logo

For the Inventor, By the Inventor

Shanghai, China

Hutchison Medipharma Limited


USPTO Granted Patents = 33



Forward Citations = 32

Loading Chart...
Loading Chart...

34 inventors (with patents filed for the assignee):

goldMedal Wei-Guo Su (21 out of 33 patents)

silverMedal Guangxiu Dai (13 out of 14 patents)

bronzeMedal Zhenping Wu (8 out of 9 patents)

4.  Wenji Li (8 out of 9 patents)

5.  Weihan Zhang (8 out of 24 patents)

6.  Hong Jia (7 out of 13 patents)

7.  Kun Xiao (6 out of 38 patents)

8.  Wei Deng (6 out of 20 patents)

9.  Jinshui Li (5 out of 6 patents)

10.  Ling Feng (4 out of 4 patents)

11.  Jianguo Ji (4 out of 40 patents)

12.  Yumin Cui (3 out of 11 patents)

13.  Haibin Yang (3 out of 5 patents)

14.  Yongxin Ren (3 out of 9 patents)

15.  Zhenping Tian (3 out of 3 patents)


33 patents:

1. 12492210 - Tricyclic compounds and their use (2025-12-09),
2. 12435062 - Amide compounds and uses thereof (2025-10-07),
3. 12234211 - Cycloolefin substituted heteroaromatic compounds and their use (2025-02-25),
4. 12180214 - Crystalline forms of (s)-4-amino-6-((1-(3-chloro-6-phenylimidazo[1,2-b]pyridazine-7-yl)ethyl)amino)pyrimidine-5-carbonitrile as inhibitors of phosphatidylinositol-3-kinase (2024-12-31),
5. 12173008 - Substituted piperazines as BTK inhibitors (2024-12-24),
6. 12134613 - Method for the manufacture of 3-[(1S)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine and polymorphic forms thereof (2024-11-05),
7. 12084441 - Salts of a compound and the crystalline forms thereof (2024-09-10),
8. 12070457 - Substituted pyridines, pyridazines, pyrimidines, and 1,2,3-triazines as bruton's tyrosine kinase inhibitors (2024-08-27),
9. 12030951 - Anti-OX40 antibody and uses thereof (2024-07-09),
10. 11896592 - Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor (2024-02-13),
11. 11655254 - Substituted piperazines as BTK inhibitors (2023-05-23),
12. 11584750 - Crystalline forms of (S)-4-amino-6-((1-(3-chloro-6-phenylimidazo[1,2-b]pyridazine-7-yl)ethyl)amino)pyrimidine-5-carbonitrile as inhibitors of phosphatidylinositol-3-kinase (2023-02-21),
13. 11478474 - 2-(3'-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4′-bipyridin]-2′-yl)-7,7-dimethyl-7,8-dihydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one as a BTK inhibitor (2022-10-25),
14. 11414390 - Cycloolefin substituted heteroaromatic compounds and their use (2022-08-16),
15. 11396507 - Salts of a compound and the crystalline forms thereof (2022-07-26),
Hutchison Medipharma Limited (Hutchison MediPharma) is a biopharmaceutical company specializing in the discovery and development of innovative therapeutics for the treatment of various diseases. With a focus on oncology and autoimmune diseases, Hutchison MediPharma utilizes cutting-edge research and collaborations with industry partners to drive advancements in the field of medicine. Through a portfolio of pipeline candidates and strategic partnerships, Hutchison MediPharma aims to improve patient outcomes and contribute to the advancement of healthcare.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

...
33 Patents

#88 in Shanghai

#857 in China

#19,570 in the World

...
Shanghai, China

Hutchison Medipharma Limited

Forward Citations = 32

34 inventors:

goldMedal Wei-Guo Su (21 out of 33 patents)

silverMedal Guangxiu Dai (13 out of 14 patents)

bronzeMedal Zhenping Wu (8 out of 9 patents)

4.  Wenji Li (8 out of 9 patents)

5.  Weihan Zhang (8 out of 24 patents)

Please report any incorrect information to support@idiyas.com
Loading…